Acute Coronary Syndrome
Alirocumab significantly decreased severe cardiovascular risks in patients with acute coronary syndrome.
Low-risk acute coronary syndrome patients may require fewer referrals for invasive coronary angiography if they had initial noninvasive testing such as stress echocardiography or cardiovascular magnetic resonance.
Same-day discharge after percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes was not predictive of 30-day readmission, death, or bleeding.
The use of a decision aid in patients at risk of acute coronary syndrome increased patient knowledge about their risk.
Only 5.5% of ER patients are diagnosed with 1 of 6 life threatening conditions.
The HEART pathway app provides doctors in the ED with a digital application an already proven method of assessment.
Ticagrelor significantly reduced the rate of cardiovascular death, MI or stroke compared with clopidogrel in a clinical trial.